Abstract
Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Current Cancer Therapy Reviews
Title: Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Volume: 2 Issue: 1
Author(s): Zakir Khan, Pratiksha Bhadouria, Radha Gupta and Prakash S. Bisen
Affiliation:
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Abstract: Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Bhadouria Pratiksha, Gupta Radha and Bisen S. Prakash, Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406777592113
DOI https://dx.doi.org/10.2174/157339406777592113 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Cell-in-cell phenomenon: A New Paradigm in Life Sciences.
Current Molecular Medicine Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry New Developments in the Management of Pleural Effusions
Current Respiratory Medicine Reviews Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition